These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39167623)

  • 21. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
    Okamoto I; Sato H; Tsukahara K
    Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.
    Harrington KJ; Kong A; Mach N; Chesney JA; Fernandez BC; Rischin D; Cohen EEW; Radcliffe HS; Gumuscu B; Cheng J; Snyder W; Siu LL
    Clin Cancer Res; 2020 Oct; 26(19):5153-5161. PubMed ID: 32669371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.
    Neal J; Pavlakis N; Kim SW; Goto Y; Lim SM; Mountzios G; Fountzilas E; Mochalova A; Christoph DC; Bearz A; Quantin X; Palmero R; Antic V; Chun E; Edubilli TR; Lin YC; Huseni M; Ballinger M; Graupner V; Curran D; Vervaet P; Newsom-Davis T
    J Clin Oncol; 2024 Jul; 42(20):2393-2403. PubMed ID: 38552197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study.
    Forster MD; Dillon MT; Kocsis J; Remenár É; Pajkos G; Rolland F; Greenberg J; Harrington KJ
    Eur J Cancer; 2019 Dec; 123():36-47. PubMed ID: 31648099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors.
    Dayyani F; Chao J; Lee FC; Taylor TH; Neumann K; Cho MT
    Oncologist; 2024 Aug; 29(8):721-e1088. PubMed ID: 38823034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
    Chevalier T; Daste A; Saada-Bouzid E; Loundou A; Peyraud F; Lambert T; Le Tourneau C; Peyrade F; Dupuis C; Alfonsi M; Fayette J; Reure J; Huguet F; Fakhry N; Toullec C; Salas S
    Cancer Med; 2021 Jun; 10(12):3952-3963. PubMed ID: 34080776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.
    Koyama T; Kiyota N; Boku S; Imamura Y; Shibata N; Satake H; Tanaka K; Hayashi H; Onoe T; Asada Y; Yamazaki T; Nose T; Ohata S; Nagatani Y; Kimbara S; Funakoshi Y; Teshima M; Shinomiya H; Minami H
    ESMO Open; 2024 Jun; 9(6):103476. PubMed ID: 38833968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Park R; Li J; Slebos RJC; Chaudhary R; Poole MI; Ferraris C; Farinhas J; Hernandez-Prera J; Kirtane K; Teer JK; Song X; Hall MS; Tasoulas J; Amelio AL; Chung CH
    Oral Oncol; 2024 Jul; 154():106866. PubMed ID: 38820888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Saleh K; Daste A; Martin N; Pons-Tostivint E; Auperin A; Herrera-Gomez RG; Baste-Rotllan N; Bidault F; Guigay J; Le Tourneau C; Saada-Bouzid E; Even C
    Eur J Cancer; 2019 Nov; 121():123-129. PubMed ID: 31574417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
    Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
    Sacco AG; Chen R; Worden FP; Wong DJL; Adkins D; Swiecicki P; Chai-Ho W; Oppelt P; Ghosh D; Bykowski J; Molinolo A; Pittman E; Estrada MV; Gold K; Daniels G; Lippman SM; Natsuhara A; Messer K; Cohen EEW
    Lancet Oncol; 2021 Jun; 22(6):883-892. PubMed ID: 33989559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
    Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
    Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria.
    Swiecicki PL; Bellile EL; Brummel CV; Brenner JC; Worden FP
    Cancer; 2021 Jan; 127(2):219-228. PubMed ID: 33079405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
    Siu LL; Even C; Mesía R; Remenar E; Daste A; Delord JP; Krauss J; Saba NF; Nabell L; Ready NE; Braña I; Kotecki N; Zandberg DP; Gilbert J; Mehanna H; Bonomi M; Jarkowski A; Melillo G; Armstrong JM; Wildsmith S; Fayette J
    JAMA Oncol; 2019 Feb; 5(2):195-203. PubMed ID: 30383184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
    Rodriguez CP; Wu QV; Voutsinas J; Fromm JR; Jiang X; Pillarisetty VG; Lee SM; Santana-Davila R; Goulart B; Baik CS; Chow LQM; Eaton K; Martins R
    Clin Cancer Res; 2020 Feb; 26(4):837-845. PubMed ID: 31796519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy.
    Hellmann MD; Jänne PA; Opyrchal M; Hafez N; Raez LE; Gabrilovich DI; Wang F; Trepel JB; Lee MJ; Yuno A; Lee S; Brouwer S; Sankoh S; Wang L; Tamang D; Schmidt EV; Meyers ML; Ramalingam SS; Shum E; Ordentlich P
    Clin Cancer Res; 2021 Feb; 27(4):1019-1028. PubMed ID: 33203644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.
    Mehra R; Seiwert TY; Gupta S; Weiss J; Gluck I; Eder JP; Burtness B; Tahara M; Keam B; Kang H; Muro K; Geva R; Chung HC; Lin CC; Aurora-Garg D; Ray A; Pathiraja K; Cheng J; Chow LQM; Haddad R
    Br J Cancer; 2018 Jul; 119(2):153-159. PubMed ID: 29955135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC).
    Sun L; Cohen RB; Dimitrios Colevas A
    Oral Oncol; 2024 Nov; 158():106997. PubMed ID: 39159526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study.
    Algazi A; Papadopoulos KP; Tsai F; Hansen AR; Angra N; Das M; Sheth S; Siu LL
    ESMO Open; 2024 Aug; 9(8):103646. PubMed ID: 39043009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.